Jump to content
Sign in to follow this  

Researchers find possible link between micro-dosing mushrooms and creativity

Recommended Posts

Researchers find possible link between micro-dosing mushrooms and creativity

September 26, 2018


Researchers at Leiden University say they have found evidence that there may be a link between tiny doses of psychedelic drugs and creativity.

Micro-doses of drugs such as ‘magic’ mushrooms and truffles is considered to be an aid to creativity in some countries and their use is on the rise in the Netherlands.

The Leiden researchers gave tiny doses of mushroom to 38 members of the Psychedelic Society of the Netherlands and tested their ability to do certain tasks before and after taking the drug.

The tests, the researchers showed, that there was an improvement in both convergent and divergent thinking skills (which assess creativity), but, as psychologist Zsuzsika Sjoerds told the Volkskrant later, the performance in intelligence tests did not get better.

‘This is a suggestion that micro-dosing has a selective effect on creativity, otherwise it would improve everything,’ she told the paper.

Placebo effect

Nevertheless, it is too soon to conclude there is a link. ‘While this study provides quantitative support for the cognitive enhancing properties of micro-dosing psychedelics, future research has to confirm these preliminary findings in more rigorous placebo-controlled study designs,’ the researchers conclude.

Sjoerds and the rest of the team are now assessing the results of further research involving 70 people, which includes a control group, the Volkskrant said.

The research, which has not been peer reviewed and is available in pre-print format, also included scientists from Germany and the Czech Republic.

More on the trial from The Atlantic




Share this post

Link to post
Share on other sites

Recategorization recommendations for drug in hallucinogenic mushrooms

Reviewed by Alina Shrourou, BSc
Sep 26 2018

In an evaluation of the safety and abuse research on the drug in hallucinogenic mushrooms, Johns Hopkins researchers suggest that if it clears phase III clinical trials, psilocybin should be re-categorized from a schedule I drug--one with no known medical potential--to a schedule IV drug such as prescription sleep aids, but with tighter control.

The researchers summarize their analysis in the October print issue of Neuropharmacology.

"We want to initiate the conversation now as to how to classify psilocybin to facilitate its path to the clinic and minimize logistical hurdles in the future," says Matthew W. Johnson, Ph.D., associate professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine. "We expect these final clearance trials to take place in the next five years or so."

Following the Controlled Substances Act of 1970, any drug with the potential for abuse is categorized based on criteria that take into account whether the drug has accepted medical use, and its safety and the potential for abuse. Although preliminary research studies suggest that psilocybin may be effective for smoking cessation and for disorders such as cancer-specific depression and anxiety, it must clear phase III clinical trials before the Food and Drug Administration can be petitioned to reclassify it.

Studies in animals and humans both show low potential for abuse, the researchers say. When rats push a lever to receive psilocybin, they don't keep pushing the lever like they do for drugs such as cocaine, alcohol or heroin. When it comes to human studies, people who have used psilocybin typically report using it a few times across their lifetime.

As for safety, studies show it frequently falls at the end of the scales with the least harm to users and society, say the researchers. Psilocybin also is lowest in the potential for lethal overdose as there is no known overdose level.

"We should be clear that psilocybin is not without risks of harm, which are greater in recreational than medical settings, but relatively speaking, looking at other drugs both legal and illegal, it comes off as being the least harmful in different surveys and across different countries," says Johnson.

That being said, although psilocybin is relatively less harmful than other drugs and not prone to compulsive abuse, the researchers don't recommend releasing psilocybin into patients' hands even with a prescription. "We believe that the conditions should be tightly controlled and that when taken for a clinical reason, it should be administered in a health care setting monitored by a person trained for that situation," says Johnson. The researchers foresee that the process for psilocybin use in the clinic would be similar to how an anesthesiologist prescribes and administers a drug, minimizing the potential for abuse or harm.




  • Like 1

Share this post

Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
Sign in to follow this  


Important Information

By using this site, you agree to our Terms of Use.